Literature DB >> 33017593

Emerging technology and platforms for cardiotoxicity testing.

Tamer M A Mohamed1, Daniel J Conklin2.   

Abstract

Entities:  

Keywords:  Anticancer drugs; Cardiomyocyte; Embryonic stem cells; High throughput; Human-induced pluripotent stem cells; Toxicity

Year:  2020        PMID： 33017593      PMCID： PMC7747951          DOI： 10.1016/j.taap.2020.115262

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN： 0041-008X            Impact factor:   4.219


× No keyword cloud information.
  12 in total

1.  Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality.

Authors:  C Arden Pope; Michelle C Turner; Richard T Burnett; Michael Jerrett; Susan M Gapstur; W Ryan Diver; Daniel Krewski; Robert D Brook
Journal:  Circ Res       Date:  2014-10-27       Impact factor: 17.367

Review 2.  Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.

Authors:  Li Pang; Philip Sager; Xi Yang; Hong Shi; Frederick Sannajust; Mathew Brock; Joseph C Wu; Najah Abi-Gerges; Beverly Lyn-Cook; Brian R Berridge; Norman Stockbridge
Journal:  Circ Res       Date:  2019-10-10       Impact factor: 17.367

Review 3.  Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes.

Authors:  Claire Robertson; David D Tran; Steven C George
Journal:  Stem Cells       Date:  2013-05       Impact factor: 6.277

4.  Low doses of BPA induced abnormal mitochondrial fission and hypertrophy in human embryonic stem cell-derived cardiomyocytes via the calcineurin-DRP1 signaling pathway: A comparison between XX and XY cardiomyocytes.

Authors:  Wei Cheng; Shoufei Yang; Xiaolan Li; Fan Liang; Ren Zhou; Hui Wang; Yan Feng; Yan Wang
Journal:  Toxicol Appl Pharmacol       Date:  2019-12-09       Impact factor: 4.219

5.  A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.

Authors:  Brian B Hasinoff; Daywin Patel; Xing Wu
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-15       Impact factor: 4.219

6.  Resveratrol protects against PM2.5-induced heart defects in zebrafish embryos as an antioxidant rather than as an AHR antagonist.

Authors:  Fei Ren; Yujie Huang; Yizhou Tao; Cheng Ji; Stanley Aniagu; Yan Jiang; Tao Chen
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-05       Impact factor: 4.219

7.  Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay.

Authors:  Pierre Morissette; Sebastian Polak; Anne Chain; Jin Zhai; John P Imredy; Mary Jo Wildey; Jeffrey Travis; Kevin Fitzgerald; Patrick Fanelli; Elisa Passini; Blanca Rodriguez; Frederick Sannajust; Christopher Regan
Journal:  Toxicol Appl Pharmacol       Date:  2020-01-23       Impact factor: 4.219

Review 8.  Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2016-02-04       Impact factor: 8.775

Review 9.  Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development.

Authors:  Bernard Fermini; Shawn T Coyne; Kevin P Coyne
Journal:  SLAS Discov       Date:  2018-06-04       Impact factor: 3.341

10.  A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm.

Authors:  Bradley J Ridder; Derek J Leishman; Matthew Bridgland-Taylor; Mohammadreza Samieegohar; Xiaomei Han; Wendy W Wu; Aaron Randolph; Phu Tran; Jiansong Sheng; Timm Danker; Anders Lindqvist; Daniel Konrad; Simon Hebeisen; Liudmila Polonchuk; Evgenia Gissinger; Muthukrishnan Renganathan; Bryan Koci; Haiyang Wei; Jingsong Fan; Paul Levesque; Jae Kwagh; John Imredy; Jin Zhai; Marc Rogers; Edward Humphries; Robert Kirby; Sonja Stoelzle-Feix; Nina Brinkwirth; Maria Giustina Rotordam; Nadine Becker; Søren Friis; Markus Rapedius; Tom A Goetze; Tim Strassmaier; George Okeyo; James Kramer; Yuri Kuryshev; Caiyun Wu; Herbert Himmel; Gary R Mirams; David G Strauss; Rémi Bardenet; Zhihua Li
Journal:  Toxicol Appl Pharmacol       Date:  2020-03-21       Impact factor: 4.219
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.